Represented Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical biotechnology company developing a novel and patented systemically administered anti-cancer and anti-viral immunotherapy, in an at-the-market equity offering program under which the Company may offer and sell, from time to time, its shares of Common Stock having an aggregate offering price of up to $100 million.
McCarter & English, LLP | Contents of this website may contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.